Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?
Open Access
- 9 January 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 9, 1070383
Abstract
Bladder cancer (BlCa) is a highly immunogenic cancer. Bacillus Calmette-Guérin (BCG) is the standard treatment for non-muscle invasive bladder cancer (NMIBC) patients and, recently, second-line immunotherapies have arisen to treat metastatic BlCa patients. Understanding the interactions between tumor cells, immune cells and soluble factors in bladder tumor microenvironment (TME) is crucial. Cytokines and chemokines released in the TME have a dual role, since they can exhibit both a pro-inflammatory and anti-inflammatory potential, driving infiltration and inflammation, and also promoting evasion of immune system and pro-tumoral effects. In BlCa disease, 70–80% are non-muscle invasive bladder cancer, while 20–30% are muscle-invasive bladder cancer (MIBC) at the time of diagnosis. However, during the follow up, about half of treated NMIBC patients recur once or more, with 5–25% progressing to muscle-invasive bladder cancer, which represents a significant concern to the clinic. Epithelial-mesenchymal transition (EMT) is one biological process associated with tumor progression. Specific cytokines present in bladder TME have been related with signaling pathways activation and EMT-related molecules regulation. In this review, we summarized the immune landscape in BlCa TME, along with the most relevant cytokines and their putative role in driving EMT processes, tumor progression, invasion, migration and metastasis formation.Keywords
Funding Information
- Instituto Português de Oncologia do Porto (CI-IPOP-FBGEBC-27 CI-IPOP-PI-137)
- Associazione Italiana per la Ricerca sul Cancro (AIRC IG17217)
- Università degli Studi della Campania Luigi Vanvitelli (2020-UNA2CLE-0203198)
- Fundação para a Ciência e a Tecnologia (CEECINST/00091/2018)
This publication has 169 references indexed in Scilit:
- Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancersBMC Cancer, 2013
- IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder CancerPLOS ONE, 2013
- The Dendritic Cell Response to Classic, Emerging, and Homeostatic Danger Signals. Implications for AutoimmunityFrontiers in Immunology, 2013
- Mechanisms by Which Interleukin-6 Attenuates Cell Invasion and Tumorigenesis in Human Bladder Carcinoma CellsBioMed Research International, 2013
- Interleukin-8 (IL-8) over-production and autocrine cell activation are key factors in monomethylarsonous acid [MMA(III)]-induced malignant transformation of urothelial cellsToxicology and Applied Pharmacology, 2012
- FOXP3 and survival in urinary bladder cancerBJU International, 2011
- Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic2010
- CD56bright natural killer (NK) cells: an important NK cell subsetImmunology, 2009
- Cytokines, Inflammation, and PainInternational Anesthesiology Clinics, 2007
- Transforming growth factor-β in cancer and metastasisCancer and Metastasis Reviews, 2006